Fewer than 10% of patients who could benefit from weight-loss injections like Wegovy have access to them, caution the global health agency as it publishes its first advice on the drugs.
Given in excess of 1,000,000,000 individuals worldwide now living with obesity, it is advocating for broader and more equitable access to these injectable treatments.
Based on projections, in excess of 2,000,000,000 are projected to be obese by 2030 if no action is taken.
"The latest guidance affirms that excess weight is a chronic disease that can be treated with comprehensive and lifelong support," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and supply-chain constraints are key barriers to widespread access to the injections that can aid individuals in losing significant body mass, says the body.
GLP-1 Therapy Scarcity
Even under the current most favorable case, the production of these medications would only suffice for around 100 million people – less than 10% of eligible patients, per the health organization.
The advice encourages nations and manufacturers to expand access, through measures such as patent sharing.
Exclusive production rights on a key compound – the main ingredient of a leading brand – is set to lapse in several countries in 2026.
The Way Obesity Drugs Work
The injections imitate a biological compound to slow digestion, suppress the appetite and enhance the sense of being full so individuals reduce food intake.
Patients commonly see weight reduction after several weeks of starting on the weekly injections.
Studies points to users may regain a significant portion within a year of discontinuing the drug, as their usual food cravings return.
Being carrying excess weight elevates your likelihood for experiencing health problems, like diabetes, cardiovascular issues, stroke, and certain cancers.
Obesity impacts individuals in all nations and was linked to over three and a half million deaths worldwide in 2024, per the WHO.
